Vial Doses First Patient with Asthma in Phase 1b Study of Vial's IL-13 x TSLP, a Bispecific Antibody Designed for Twice-Yearly Dosing

Phase 1IL-13 x TSLPPositive

AI Analysis

Summary

Vial dosed the first patient with asthma in a Phase 1b study of its IL-13 x TSLP bispecific antibody, a half-life-extended candidate designed for twice-yearly dosing. Phase 1a data in healthy volunteers at doses of 15–800 mg IV supported progression to patient studies.

Clinical Trial Data

Phase

Outcome Details

First patient dosed in Phase 1b study

Importance:5/10

Sentiment:

0.60

bispecific antibodyIL-13TSLPasthmaType 2 inflammationhalf-life extendedtwice-yearly dosing

Related Companies

$HOST $TRAX

Read the original article

Published by PR Newswire Pharma on October 5, 2026 3:42 PM

Read Original